Skip to content
Menu

Argus Research Upgrades Elevance Health to Buy, Announces $510 Price Target

Benzinga Newsdesk 1 hour ago

Analyst RatingsNewsUpgradesPrice TargetHot

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Argus Research analyst David Toung upgrades Elevance Health (NYSE:ELV) from Hold to Buy and announces $510 price target.

Argus Research analyst David Toung upgrades Elevance Health (NYSE:ELV) from Hold to Buy and announces $510 price target.

Read at benzinga.com